May 11, 2010 |
Reporting from Chicago After decades of research and multiple failed attempts to find a treatment, the pharmaceutical industry is entering a crucial phase in the search for a drug that can slow, or stop, the progression of Alzheimer's disease. Drug makers see huge moneymaking potential because of the aging population. Alzheimer's afflicts more than 5 million Americans and is one of the leading causes of death in the United States, according to the Centers for Disease Control and Prevention.
March 6, 2007 |
Rep. Henry A. Waxman (D-Los Angeles) opened an investigation of research and marketing related to medical devices and drugs made by Boston Scientific Corp., Johnson & Johnson, Eli Lilly & Co., AstraZeneca and Cephalon Inc. The companies received letters from Waxman, chairman of the House Oversight and Government Reform Committee, asking for documents including correspondence with the Food and Drug Administration.
November 8, 2008
Re "Memos shed light on drug lawsuit dispute," Oct. 30, and "High court looks split on suits against drug makers," Nov. 4 Your article provides support for why injured consumers must be allowed to bring lawsuits against drug companies that market unsafe drugs. The documents described in the article show top career FDA officials internally expressing strong concern about the agency's rules immunizing drug companies from liability. This is an unprecedented policy advocated by the current White House, and the U.S. Supreme Court is now considering its legitimacy.
June 21, 2009 |
U.S. drug makers agreed Saturday to shell out $80 billion over the next 10 years to lower the cost of medication for seniors and help pay for President Obama's proposed healthcare overhaul, as part of an agreement hashed out with lawmakers and administration officials. The deal means the pharmaceutical companies will extend discounts on prescription drugs to millions of seniors who often must pay staggering drug costs not covered by their Medicare plan, according to a White House announcement.
March 17, 2008 |
For the makers of brand-name prescription drugs, generic competition is about as welcome as a virus. In the first year that a generic competitor goes on the market, a brand-name drug loses on average more than half of its market share, and its price drops with each new generic company that produces a copycat, May 2005 study said. So companies that are about to face that competition have big incentives to delay the entry of new generics to the market -- and to erect obstacles to switching to the cheaper upstarts.
April 29, 2003 |
U.S. officials issued final guidelines warning drug makers that some marketing practices, including gifts or payments to doctors, may run afoul of anti-kickback laws. Two "suspect" practices identified by the voluntary guidelines are payments from a company to physicians or pharmacists to switch patients to the manufacturer's drug and payments to doctors to listen to a pitch from a drug company representative.